ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

VXRT Vaxart Inc

0.71
0.0516 (7.84%)
27 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Vaxart Inc NASDAQ:VXRT NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.0516 7.84% 0.71 0.71 0.74 0.7097 0.6603 0.6985 1,321,643 01:00:00

Biota to Present at the Jefferies 2014 Global Healthcare Conference

28/05/2014 2:58pm

GlobeNewswire Inc.


Vaxart (NASDAQ:VXRT)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Vaxart Charts.

Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company") today announced that its Executive Vice President, Dr. Joseph Patti, will present a corporate update at the Jefferies 2014 Global Healthcare Conference on Monday, June 2nd at 8:00 AM ET at The Grand Hyatt Hotel in New York City.

The presentation will be webcast live and may be accessed through the Investor Relations' Events and Presentations section on Biota's website at www.biotapharma.com. Please go to the website at least 15 minutes prior to the event to register, download and install any necessary audio/video software. An archived replay will also be available for 30 days following the live presentation.

About Biota

Biota Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of products to prevent and treat serious and potentially life-threatening infectious diseases. The Company currently has two Phase 2 clinical-stage product candidates: laninamivir octanoate, which the Company is developing for the treatment of influenza A and B infections under an IND in the United States; and vapendavir, a potent, oral broad spectrum capsid inhibitor of enteroviruses, including human rhinovirus. In addition to these clinical-stage development programs, the Company has preclinical programs focused on developing treatments for respiratory syncytial virus. For additional information about the Company, please visit www.biotapharma.com.

Biota is a registered trademark of Biota Pharmaceuticals, Inc.

CONTACT: Russell H. Plumb
         Chief Executive Officer
         (678) 221-3351
         r.plumb@biotapharma.com
         
         Lee M. Stern
         The Trout Group
         (646) 378-2922
         lstern@troutgroup.com

1 Year Vaxart Chart

1 Year Vaxart Chart

1 Month Vaxart Chart

1 Month Vaxart Chart

Your Recent History

Delayed Upgrade Clock